Article

Updates in the Treatment of Waldenström Macroglobulinemia

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Related Content
Mark R. Litzow, MD
July 24th 2024

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
July 23rd 2024

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Michal Taszner, MD
July 17th 2024

Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma

Brentuximab Vedotin Triplet in R/R DLBCL Subgroups | Image Credit: © freshidea - stock.adobe.com
July 17th 2024

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups